SCHEMBL20146480

SCHEMBL20146480

C[C@H]1CN(Cc2ccccc2)C1C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.50
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
POLB P06746 1/20 0.41
BRD4 O60885 2/20 0.39
ABCB1 P08183 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17986811 1.00 MAPT (0.50) MAPTPDK1PDK2PDK3PDK4
SCHEMBL30636976 1.00 MAPT (0.50) MAPTPDK1PDK2PDK3PDK4
SCHEMBL22039864 1.00 MAPT (0.50) MAPTPDK1PDK2PDK3PDK4
SCHEMBL22039863 1.00 MAPT (0.50) MAPTPDK1PDK2PDK3PDK4
SCHEMBL1947707 1.00 MAPT (0.50) MAPTPDK1PDK2PDK3PDK4
Hydrochloric Acid SCHEMBL28654829 0.99 MAPT (0.49) MAPTPDK1PDK2PDK3PDK4
SCHEMBL23717687 0.88 TP53 (0.42) MAPTKMT2AL3MBTL1ALDH1A1
SCHEMBL23717686 0.84 CACNA1B (0.36) MAPTPDK1PDK2PDK3PDK4
SCHEMBL17986812 0.82 MAPT (0.58) MAPTPDK1PDK2PDK3PDK4
SCHEMBL20135465 0.82 MAPT (0.58) MAPTPDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3560932-B1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES OF SAME JAPAN TOBACCO INC (JP) 2026-03-11 EP disclosed
US-20250084106-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF LEO PHARMA A/S (DK) 2025-03-13 US disclosed
US-12195481-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAPAN TOBACCO INC. (JP) 2025-01-14 US disclosed
EP-3321271-B1 METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF JAPAN TOBACCO INC (JP) 2024-05-29 EP disclosed
US-20240140967-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF LEO PHARMA A/S (DK) 2024-05-02 US disclosed
CN-117865992-A Process for preparing 7H-pyrrolo [2,3-d ] pyrimidine derivatives and synthetic intermediates therefor 日本烟草产业株式会社 2024-04-12 CN disclosed
CN-110300756-B Process for preparing 7H-pyrrolo [2,3-d ] pyrimidine derivatives and synthetic intermediates therefor 日本烟草产业株式会社 2024-01-02 CN disclosed
US-11673900-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAPAN TOBACCO INC. (JP) 2023-06-13 US disclosed
US-11673900-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAPAN TOBACCO INC. (JP) 2023-06-13 US disclosed
US-11673900-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAPAN TOBACCO INC. (JP) 2023-06-13 US disclosed
US-11339181-B2 Crystalline forms of a Janus kinase inhibitor JAPAN TOBACCO INC. (JP) 2022-05-24 US disclosed
US-11312728-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof JAPAN TOBACCO INC. (JP) 2022-04-26 US disclosed
US-11312728-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof JAPAN TOBACCO INC. (JP) 2022-04-26 US disclosed
CN-107709337-B Process for the preparation of 7H-pyrrolo [2, 3-d ] pyrimidine derivatives and intermediates therefor 日本烟草产业株式会社 2021-11-16 CN disclosed
US-10822354-B2 Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof JAPAN TOBACCO INC. (JP) 2020-11-03 US disclosed
US-20200216470-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF JAPAN TOBACCO INC. (JP) 2020-07-09 US disclosed
US-20200165269-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF SHIONOGI & CO., LTD. (JP) 2020-05-28 US disclosed
EP-3560932-A1 METHOD FOR PRODUCING 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AND SYNTHETIC INTERMEDIATE OF SAME Japan Tobacco, Inc. (JP) 2019-10-30 EP disclosed
WO-2018117153-A1 CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR JAPAN TOBACCO INC. (JP) 2018-06-28 WO disclosed
EP-3321271-A1 METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF Japan Tobacco, Inc. (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312728-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof JAK1, JAK3, JAK2 MAPT 2810/4885PDK1 192/4885PDK2 185/4885
US-11673900-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAK1, JAK3, JAK2 MAPT 3780/4885PDK1 117/4885PDK2 167/4885
US-11339181-B2 Crystalline forms of a Janus kinase inhibitor JAK1, JAK3, JAK2 MAPT 2011/4885PDK1 854/4885PDK2 1379/4885
US-20200216470-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF JAK1, JAK3, JAK2 MAPT 3780/4885PDK1 117/4885PDK2 167/4885
US-12195481-B2 Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof JAK1, JAK3, JAK2 MAPT 3780/4885PDK1 117/4885PDK2 167/4885
US-20240140967-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF JAK1, JAK3, JAK2 MAPT 3780/4885PDK1 117/4885PDK2 167/4885
US-10822354-B2 Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof JAK1, JAK3, JAK2 MAPT 3815/4885PDK1 184/4885PDK2 208/4885
US-20250084106-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF JAK1, JAK3, JAK2 MAPT 3780/4885PDK1 117/4885PDK2 167/4885
US-20200165269-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF JAK1, JAK3, JAK2 MAPT 2810/4885PDK1 192/4885PDK2 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.